EUVIMEDEUVIMED entdecken
Crossref

Effect of CMV Mismatch on Heart Transplant Outcomes Using a Surveillance and Preemptive Strategy

Guy A MacGowan iD, Julie Samuel, Adam McDiarmid, Oscar Gonzalez-Fernandez iD, Gareth Parry

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15419 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Guy A MacGowan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiothoracic Board, Freeman Hospital, Newcastle upon Tyne Hospital Trust, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Heart Transplantation, Cytomegalovirus Infections, Cytomegalovirus, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The aim of the study was to determine outcomes after heart transplantation for cytomegalovirus (CMV) mismatched patients (D + /R − ) who underwent a surveillance and preemptive therapy protocol, compared to nonmismatch patients.

Methods

A review of patient records from January 2010 to December 2020 with follow‐up to October 2023 was done. The protocol consisted weekly surveillance with CMV PCR starting 4 weeks after transplant continuing up until the patient seroconverts or up to 3 months posttransplant if the patient does not seroconvert. Valganciclovir was given for 2 weeks to those who seroconverted.

Results

Two hundred and twenty‐one patients were included, and 23% were mismatched patients. Overall survival was not different between CMV groups ( p = NS). Causes of death and morbidities were also not significantly different ( p = NS). Sixty‐six percent of mismatch patients seroconverted, and there was also a significantly older donor age in the seroconverted patients compared to nonseroconverted patients (41 ± 11 vs. 29 ± 12 years, p < 0.005), indicating a higher risk donor profile. A multivariate Cox regression including donor age showed that there was no increase in mortality in the seroconverted mismatches compared to nonmismatch patients ( p = NS).

Conclusions

There is no significant increased mortality or morbidity using a CMV surveillance and preemptive therapy protocol. The effect of donor age on seroconversion of mismatches requires further validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart TransplantationCytomegalovirus InfectionsCytomegalovirusAntiviral AgentsGraft SurvivalHumansFemaleMaleFollow-Up StudiesAdultPrognosisRetrospective StudiesRisk FactorsGraft RejectionSurvival RateMiddle AgedPostoperative ComplicationsTissue Donors

Stichwörter der Autor:innen

CMVheart transplantoutcomes

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Cardiothoracic Board, Freeman Hospital, Newcastle upon Tyne Hospital Trust, Newcastle upon Tyne, UK.
  • Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Department of Microbiology, Freeman Hospital, Newcastle upon Tyne Hospital Trust, Newcastle upon Tyne, UK.

ORCID-Profile: Guy A MacGowan, Oscar Gonzalez-Fernandez

Zitieren

APA

MacGowan, G. A., Samuel, J., McDiarmid, A., Gonzalez-Fernandez, O., & Parry, G. (2024). Effect of CMV Mismatch on Heart Transplant Outcomes Using a Surveillance and Preemptive Strategy. Clinical Transplantation. https://doi.org/10.1111/ctr.15419

Vancouver

MacGowan GA, Samuel J, McDiarmid A, Gonzalez-Fernandez O, Parry G. Effect of CMV Mismatch on Heart Transplant Outcomes Using a Surveillance and Preemptive Strategy. Clinical Transplantation. 2024. doi:10.1111/ctr.15419

BibTeX
@article{MacGowan2024,
  author = {MacGowan, Guy A and Samuel, Julie and McDiarmid, Adam and Gonzalez-Fernandez, Oscar and Parry, Gareth},
  title = {Effect of CMV Mismatch on Heart Transplant Outcomes Using a Surveillance and Preemptive Strategy},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15419}
}
Kostenlos starten →